Ascorbic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ascorbic Acid: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation
One-Sentence Summary
Ascorbic acid (Vitamin C, DB00126) is an essential micronutrient widely used to prevent and treat vitamin C deficiency (scurvy), supporting collagen synthesis, antioxidant defence, and numerous enzymatic processes throughout the body. The TxGNN model predicts it may be effective for Non-Syndromic Esophageal Malformation, a rare congenital structural defect such as esophageal atresia or tracheoesophageal fistula. Currently, there are 0 clinical trials and 0 publications directly supporting this repurposing direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No Singapore licence on record; ascorbic acid is generally indicated for vitamin C deficiency and scurvy |
| Predicted New Indication | Non-Syndromic Esophageal Malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this drug entry. Based on well-established pharmacological knowledge, ascorbic acid serves as an obligatory cofactor for prolyl-4-hydroxylase and lysyl hydroxylase — enzymes required for hydroxylation of procollagen, the critical step in forming stable collagen triple helices. Without adequate vitamin C, collagen synthesis is profoundly impaired, leading to the connective tissue fragility characteristic of scurvy.
Non-syndromic esophageal malformation encompasses congenital defects such as esophageal atresia (EA) and tracheoesophageal fistula (TEF), which arise from disrupted embryonic foregut morphogenesis, typically during weeks 4–8 of gestation. The theoretical connection proposed by TxGNN rests on the idea that ascorbic acid, as an indispensable cofactor in foetal connective tissue development, could theoretically influence the structural integrity of the developing oesophageal wall during embryogenesis.
However, this mechanistic link is extremely indirect and remains entirely speculative. No clinical studies, animal models, or epidemiological data have directly connected vitamin C deficiency — or supplementation — with the incidence or severity of congenital oesophageal malformations. The high TxGNN score most likely reflects topological proximity in the knowledge graph between ascorbic acid and collagen/connective-tissue nodes, rather than a validated biological relationship. This prediction is therefore classified as model inference only (L5) and does not support clinical investigation at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is zero clinical or preclinical evidence directly linking ascorbic acid to non-syndromic esophageal malformation. The mechanistic rationale is speculative and derived entirely from knowledge-graph topology; ascorbic acid's role in collagen synthesis does not constitute a plausible therapeutic or preventive pathway for a congenital structural anomaly driven by embryonic morphogenetic failure.
To proceed, the following is needed:
- Preclinical studies (animal or organoid models) explicitly investigating whether vitamin C deficiency or supplementation during early embryogenesis affects oesophageal structural development
- Mechanistic studies that establish a direct biological link between ascorbic acid insufficiency and EA/TEF pathogenesis
- Detailed mechanism of action data (MOA) retrieved from DrugBank API (Data Gap DG002)
- Safety and regulatory information from the product package insert (Data Gap DG001)
- Singapore Health Sciences Authority (HSA) registration review, given that ascorbic acid currently holds no Singapore licence
Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.